CAMBRIDGE, Mass., June 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, and MM-398, a nanoliposomal encapsulation of irinotecan, at the 14th World Conference on Lung Cancer, taking place July 3 – 7, 2011, in Amsterdam, The Netherlands.
MM-151 is designed to effectively block downstream signaling of the EGFR receptor, a key oncogene in various carcinomas. The poster will present pre-clinical data regarding the potency of MM-151 compared to existing monoclonal therapies targeting EGFR.
Poster #3656 presents preclinical data on the ability of MM-151 to effectively block EGFR pathway activation in in-vitro signaling and inhibit tumor cell growth in-vitro and in-vivo in lung cancer models
Poster Session: P2.070: Poster Session 2
Date/Time: Tuesday, July 5, from 12:15 PM – 2:00 PM
Location: RAI Exhibition and Convention Centre, Exhibition Hall
MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors. MM-398, in partnership with PharmaEngine, Inc., is in clinical development in colorectal, gastric and pancreatic cancer and in glioma. The poster will present preclinical data on the safety and activity of MM-398 in lung cancer xenograft models.
Poster #S420-421 presents preclinical data on MM-398's safety and activity
Oral Session: 033.03: Preclinical Models 1
Date/Time: Wednesday, July 6, from 2:30 PM – 4:00 PM
Location: Room D201
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer. Merrimack is advancing a pipeline of engineered therapeutics paired with molecular diagnostics. In addition to several pre-clinical and research-stage programs, Merrimack has five oncology candidates in clinical development or expected to enter clinical development this year: MM-398, in Phase 2 testing in partnership with PharmaEngine, Inc., MM-121, in Phase 2 testing in partnership with Sanofi, MM-111 in Phase 1 / 2 testing; and MM-302 and MM-151, which are both expected to enter Phase 1 clinical development this year. MM-398, MM-121, MM-111, MM-302 and MM-151 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. Merrimack uses its proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, to integrate the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutic s and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.
Contact: Rachel Yaroschuk, Corporate Communications, Merrimack, 617-441-7414
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424
SOURCE Merrimack Pharmaceuticals, Inc.